期刊文献+

药代动力学和药效学结合模型的研究进展 被引量:4

下载PDF
导出
摘要 药代动力学 药效学结合模型是将药代动力学和药效学结合起来研究的模型 ,能描述和预测一定剂量方案下药物的效应 时间过程 ,还能解释造成这种效应 时间过程的原因。这种结合模型可应用于药物开发的临床前和临床试验的各个阶段。在临床前试验阶段可用于评价药物的体内效价和固有活性、剂型和给药方案的选择及优化等 ;在临床试验阶段则可用于估算给药剂量 浓度 效应或毒性之间的关系 ,以及年龄、性别等对药效的影响等 ,从而满足新药开发和临床试验的要求。本文综述了近年来的药代动力学 药效学结合模型及其在药物研究开发领域中的应用。
出处 《国外医学(药学分册)》 CAS 2004年第2期103-108,共6页 Foreign Medical Sciences(Section of Pharmarcy)
基金 国家杰出青年科学基金项目 ( 3 992 5 0 3 9)
  • 相关文献

参考文献20

  • 1Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives[J]. Pharm Res, 1999, 16(2): 176- 185.
  • 2Derendorf H, Lesko LJ, Chaikin P, et al. Pharmacokinetic/pharmacodynamic modeling in drug research and development[J]. J Clin Pharmacol, 2000, 40 ( 12 Pt 2):1399- 1418.
  • 3Visser SA, Wolters FL, Gubbens-Stibbe JM, et al. Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulator: in vitro-in vivo correlations [J]. J Pharmacol Exp Ther, 2003, 304(1):88-101.
  • 4Nagaraja NV, Pechstein B, Erb K, et al. Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone(LH)suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women[J]. J Clin Pharmacol, 2003, 43(3):243-251.
  • 5Parasrampuria DA, de Boer P, Desai-Krieger D, et al.Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study[J]. J Clin Pharmacol,2003, 43(4) :406 - 413.
  • 6Auler JO Jr, Espada EB, Crivelli E, et al. Diclofenac plasma protein binding: PK-PD modeling in cardiac patients submitted to cardiopulmonary bypass[J]. Braz J Med Biol Res, 1997, 30(3) :369 - 374.
  • 7Lin S, Chien YW. Pharmacokinetic-pharmacodynamic modeling of insulin: comparison of indirect pharmacodynamic response with effect-compartment link models[J]. J Pharm Pharmacol, 2002, 54(6) :791 - 800.
  • 8Nix DE, Wilton JH, Hyatt J, et al. Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers [J].Antimicrob Agents Chemother, 1997, 41(5):1108- 1114.
  • 9Gupta SK, Ellinwood EH, Nikaido AM, et al. Simultaneous modeling of the phamacokinetic and pharmacodynamic properties of benzodiazepines [J]. J Pharmacokinet Biopharm, 1990, 18(2) :89- 102.
  • 10Furuya A, Nozawa M, Gotoh J, et al. Pharmacokinetic and pharmacodynamic analysis of TS-943, a selective non-peptide platelet glycoprotein- Ⅱ b/Ⅲ a ( GP Ⅱ b/Ⅲ a) receptor antagonist, using a nonlinear mixed effect model in dogs[J]. J Pharm Pharmacol, 2002, 54(7) :921 - 927.

同被引文献72

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部